Background. Much attention has been paid to molecule-genetic diagnostics of chronic myeloid leukemia (CML) and its treatment using new highly effective methods of therapy. The baseline characteristics of patients at primary CML diagnosis are hardly discussed in literature. Aim. To provide clinical, hematological, molecular genetic and demographic characteristics of patients obtained at primary diagnosis of CML. Patients & Methods. Characteristics of CML patients are based on data gathered by the Russian Investigational Group for CML within the international project European Treatment and Outcome Study of CML in Europe (EUTOS, the European Treatment and Outcomes Study). The study included 197 patients with newly diagnosed CML in 6 regions of the Russian Federation (Mordovia, Kirov, Perm (2 sites), Bryansk, Irkutsk, and Chita) over the period from 2009 till 2012. Results. The study demonstrated that 94 % of CML cases were diagnosed in the chronic phase (CP) and 6 % of cases in the acceleration phase (AP) and the blast crisis phase (BC). In 40 % of patients there were no clinical symptoms, and CML was suspected only due to changes in the CBC test. Fatigue was the main subjective complaint presented by 77 % of patients in the CP and 100 % of patients with the AP and BC. Peripheral blood leukocytosis, left shift to immature myeloid cells and increased granulocytic lineage in bone marrow were typical for the patients. In all patients, the CML diagnosis was confirmed by cytogenetic or molecular tests. The social and demographic characteristics of CML patients and comorbidities at diagnosis were analyzed. Conclusion. Based on the results of the study, a modern «portrait of a CML patient» was obtained. The study demonstrated that cytogenetic and molecular methods allow to diagnose CML in most patients at early stages of the disease in the absence of clinical signs of progression. The data on comorbidities require a special attention while choosing a therapy considering its duration. Demographic and social characteristics of CML patients demonstrate that they are socially active, particularly interested in retaining the working capacity and quality of life.
The aging process of the skin of the hand continuously progresses from mature to advanced age. With age, the skin of the hand becomes pigmented, dry, wrinkled with an emphasized skin pattern, the tone of the skin of the hand decreases, thinning and atrophy of adipose tissue are noted, skin elasticity is lost with the formation of an excess of hypoelastic thinned dermis. In recent years, smooth thread implants have been used to correct involutional changes in the skin of the back of the hand. The aim of the study was a morphological evaluation of the effectiveness of the correction of involutional changes in the skin of the back surface of the hand with thread implants based on polycaprolactone and poly-L-lactic acid (PCL-PLLA) with notches. Using light and electron microscopy, we studied the reaction of cells and intercellular substance to the introduction of biodegradable filaments into the subcutaneous space. It was found that implantation of PCL-PLLA filaments increases the reparative potential of tissues. 3 months after implantation, stimulation of neocollagenesis and angiogenesis in the dermis and hypodermis was noted. The functional and proliferative activity of cells increased. Mitotic activity of cells in the basal layer of the epidermis led to an increase in its thickness. A clinically confirmed effect was noted after 3 months and persisted for 18 months after implantation. Long biodegradation of the threads (1.5-2 years) helps to slow down the aging process of the skin of the back surface of the hand, prolonging the processes of tissue revitalization.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.